Here are the top 5 biosimilar articles for the week of December 6, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of December 6, 2021.
Number 5: The arrival of biosimilars for filgrastim and pegfiltrastim coincided with higher use of granulocyte colony-stimulating factor (G-CSF) for prophylaxis against febrile neutropenia, but many high-risk patients still do not receive the treatment.
Number 4: In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey ordered Samsung Bioepis to delay marketing Eticovo until 2029.
Number 3: Henlius gained approval in China for a bevacizumab biosimilar (Hanbeitai) and officials discussed combination therapy options with experimental therapy serplulimab and ophthalmology treatment.
Number 2: In a review, Sandoz researchers discussed lingering barriers that prevent insulin prices from falling to more affordable levels.
Number 1: Researchers reported findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?